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Mortality and the development of complications in patients with cirrhosis and liver insufficiency are associated with increased pro-inflammatory cytokine production. 1, 2 This association has been observed in patients with cirrhosis, chronic hepatitis, acute alcoholic hepatitis and their complications such as spontaneous bacterial peritonitis, hepatorenal syndrome as well as in patients admitted for variceal bleeding. [3] [4] [5] [6] [7] The production of pro-inflammatory cytokines is greater in patients with cirrhosis than in controls and is correlated with the severity of cirrhosis. [8] [9] [10] In addition tumor necrosis factor (TNF) -alpha production has been shown to be significantly increased in cirrhosis compared to controls in response to stimulation by the endotoxin, lipopolysaccharide (LPS). [8] [9] [10] These cytokines cause deleterious effects including neutrophil activation which plays a role in liver injury, organ failure and death. [11] [12] [13] Several experimental and clinical studies have shown the beneficial effects of pentoxifylline, a TNF-alpha synthesis inhibitor. For example, pentoxifylline administration reduces portal hypertension, 14 decreases LPS-induced liver injury, 15 improves non-alcoholic steatohepatitis, 16, 17 prevents the development of hepatorenal syndrome 18 and hepatopulmonary syndrome 19 and in a randomized trial, pentoxifylline administration improved short-term survival in patients with severe alcoholic hepatitis. 18 Thus, to validate the generalized use of pentoxifylline in patients with chronic liver disease, we performed a large controlled study in patients with cirrhosis. The aim of this trial was to study the effects of pentoxifylline on survival in patients with advanced cirrhosis and to evaluate the development of complications in these patients.
METHODS
The study was an investigator-initiated, randomized, double-blind, placebo-controlled, clinical trial conducted in 9 sites. The protocol was approved by the ethics committee (CCPPRB of Bichat-Claude-Bernard Paris, France), and all patients gave written informed consent.
Although pentoxifylline and placebo were bought from Sanofi-Aventis, Sanofi-Aventis did not ACCEPTED MANUSCRIPT
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5 participate in any part of the study, including study design, data analysis, and manuscript preparation.
Patients
Patients were enrolled between August 2004 and October 2006 and followed-up until May 2007. Eligible patients had Child-Pugh C cirrhosis i.e., of more than 9 points 20 and were older than 18. The diagnosis of cirrhosis was biopsy-proven in all patients. Exclusion criteria included: pregnant woman, patients receiving anti-coagulants or non-corticosteroid immunosuppressive drugs, patients treated for arterial hypertension, patients with severe coronary artery disease or HIV or who were hypersensitive to pentoxifylline, patients who had been transplanted or who had received pentoxifylline in the 3 months before the study and finally, patients with advanced hepatocellular carcinoma or associated illnesses with a life expectancy of less than 1 month or who could not be regularly followed-up.
Study Design
Patients were eligible for screening when admitted to hospital for at least 2 days. Patients were randomly assigned to receive either pentoxifylline (400 mg pentoxifylline tablets orally 3 times daily) in opaque capsule form or identical capsules containing the placebo. Randomization was computer-generated. The duration of therapy was 6 months. Medical management was adapted to each patient's condition. Patients were assessed clinically at baseline and every month thereafter. At each visit heart rate, mean arterial pressure and occurrence of adverse events were determined and a blood sample was obtained for biochemical and hematological measurements. Abstinence from alcohol was reported by each patient and/or his (her) family during follow-up visits. Serum TNF-alpha concentrations were measured at baseline and at 2 and 6 months.
End Points
The primary end point was mortality at 2 months. Secondary end points were: mortality at 6 months and the development of the following complications not associated with death:
bacterial infections, renal insufficiency, hepatic encephalopathy and/or gastrointestinal hemorrhage. Bacterial infection was defined by the presence of one or more of the following signs 21 : white blood cells in a normally sterile body fluid; perforated viscus; evidence of pneumonia on X-ray in association with purulent sputum; and/or a syndrome associated with a high risk of infection (e.g., ascending cholangitis). Renal insufficiency was defined by a serum creatinine concentration above 1.5 mg per deciliter (130 mol per liter). Hepatic encephalopathy was clinically defined as difficulty concentrating, asterixis or confusion. Gastrointestinal hemorrhage was defined as any hematemesis or melena in a patient who, on endoscopy, had active bleeding from esophageal or gastric varices or signs of recent bleeding.
Adverse Events
An adverse event was any event that required a diagnostic or therapeutic intervention. All adverse events, regardless of their possible association with the disease or study treatment, were recorded without knowing the randomization code.
Statistical Analysis
A total of 342 patients were considered necessary to reduce the mortality by 50% at 2 months with a beta risk of 0.10 and an alpha risk of 0.05. The main analyses were performed according to the intention to treat principle but per protocol analyses were also performed. 
Results
A total of 342 patients underwent randomization. Seven patients dropped out; these patients did not take any tablets and were excluded from analysis ( Figure 1 ). Of the remaining 335 patients, 164 received pentoxifylline and 171 received placebo. Three patients in the pentoxifylline group were lost to follow up (2 at 1 month and 1 at 2 months) and 3 in the placebo group (1 at 2 months, 1 at 3 months and 1 at 5 months).
The mean duration of treatment in the pentoxifylline group was 149 days (95% for non-survivors (P<0.0001).
Baseline characteristics and treatments of patients in the 2 treatment groups are summarized in Table 1 . Abstinence from alcohol was not different between the 2 groups (P = 0.61); it was 31.1% in the pentoxifylline group and 35.7%.in the placebo group. Biochemical and hematological changes were not significantly different between the 2 groups compared to baseline values. At 2 and 6 months, serum TNF-alpha levels were not significantly different in patients in the pentoxifylline group, 17 pg/ml (95% CI, 13 to 19 pg/ml) than in the placebo group, 13 pg/ml (95% CI, 13 to 17 pg/ml) (P=0.28) and 13 pg/ml (95% CI, 10 to 17 pg/ml) vs. 11 pg/ml (95% CI, 10 to 18 pg/ml), respectively (P=0.70). At 6 months but not at 2 months, if the entire cohorte was included, basal values for serum TNF-alpha levels were significantly different between survivors (16 pg/ml [95% CI, 14 to 18 pg/ml]) and non-survivors (19 pg/ml [95% CI, 16
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Mortality
At 2 months, 28 patients had died in the pentoxifylline group and 31 in the placebo group.
At 2 months 83.5% of the patients in the pentoxifylline group and 81.8% in the placebo group survived; the difference was not significant (Table 2 and Figure 2 ).
At 6 months 70.0% of patients in the pentoxifylline group and 68.5% in the placebo group survived; the difference was not significant ( Table 2 and Figure 2 ). Seventy eight percent died of liver failure with or without sepsis and renal insufficiency, 13% died of gastrointestinal hemorrhage and 9% of other causes. The cause of death was not significantly different between the 2 groups.
In patients without hepatocellular carcinoma, 86.7% (95% CI, 81.2 to 92.3%) and 73.3%
(95% CI, 66.1 to 80.6%) survived at 2 and 6 months, respectively in the pentoxifylline group and 83.1% (95% CI, 77.3 to 88.9%) and 75.4% (95% CI, 68.4 to 82.5%), respectively in the placebo group. The differences were not significant between the 2 groups (P = 0.52 for both).
In the 133 patients enrolled in the study with acute alcoholic hepatitis, 87.3% (95% CI, 79.6 to 95.1%) and 77.5% (95% CI, 67.8 to 87.1%) survived at 2 and 6 months, respectively in the pentoxifylline group (N = 71) and 85.4% (95% CI, 76.7 to 94.2%) and 71.0% (95% CI, 59.7 to 82.3%), respectively in the placebo group (N = 62). The differences were not significant between the 2 groups (P = 0.75 and 0.59, respectively). In the 78 patients enrolled with acute alcoholic hepatitis who were not taking corticosteroid therapy because of a Maddrey discriminant factor below 32, the probabilities of patients surviving at 2 and 6 months were 91.1% (95% CI, 82.8 to 99.4%) and 77.8% (95% CI, 65.6 to 89.9%), respectively in the pentoxifylline group (N=45) and 87.9% (95% CI, 76.7 to 99.0%) and 66.7% (95% CI, 50.6 to 82.8%), respectively in the placebo group (N=33).The differences were not significant between the 2 groups (P=0.59
and 0.33, respectively). In the 55 patients enrolled with acute alcoholic hepatitis who were taking ACCEPTED MANUSCRIPT
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corticosteroid therapy because of a Maddrey discriminant factor of more than 32, the probabilities of patients surviving at 2 and 6 months were 84.6% (95% CI, 70. For the whole group of patients 11 factors were significantly associated with mortality in univariate analysis (Table 3) . Factors significantly associated with mortality in multivariate analysis were older age (P=0.004), greater Model for End-Stage Liver Disease (MELD) score (P<0.0001) and the presence of early hepatocellular carcinoma (P=0.004).
The proportion of patients who took more than 80% of the treatment dose more than 80% of the time in the pentoxifylline and placebo groups were respectively: 71% and 88% at 2 months (P<0.0001), and 58% and 75% at 6 months (P=0.007). There was no significant difference in mortality between the 2 groups by per protocol analysis, whatever the subgroup studied except for the subgroup of patients who were not being treated with antibiotics or betablockers. In this subgroup, 90.0% (95% CI, 76.9 to 100%) of patients survived at 6 months in the pentoxifylline group (N = 43) and 56.3% (95% CI, 39.1 to 73.4%) in the placebo group (n = 40) (P=0.02).
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Occurrence of liver-related complications
The proportion of patients without liver-related complications at 2 and 6 months was The risk of bacterial infection was significantly lower at 2 months in the pentoxifylline group than in the placebo group but was not significantly different at 6 months ( Table 2 ). The risk of developing renal insufficiency was not significantly different between the 2 groups at 2 months but was significantly lower in the pentoxifylline group than in the placebo group at 6 months ( Table 2 ). The risk of hepatic encephalopathy was significantly lower at 2 and 6 months in the pentoxifylline group than in the placebo group ( Table 2 ). The risk of gastrointestinal hemorrhage was not significantly different between the 2 groups at 2 and 6 months ( Table 2 ). In univariate analysis, baseline serum TNF-alpha levels and the absence of treatment with pentoxifylline were significantly associated with the development of complications (P=0.03 and P=0.004, respectively). In multivariate analysis, only the absence of treatment with pentoxifylline was associated with the development of complications (P=0.004).
Adverse Events
In the pentoxifylline group adverse events occurred in 7 patients (diarrhea, vomiting, epigastric pain or all); the drug was discontinued within the first month in these patients. In the placebo group adverse events occurred in 4 patients (epigastric pain in 2 and skin rash in 2); the drug was discontinued in 2 (epigastric pain in 1 and skin rash in 1). In 4 pentoxifylline treated
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patients, the dose was reduced to 2 tablets daily within the first month because of epigastric pain or vomiting. None of the complications was fatal.
Discussion
In this trial pentoxifylline was prescribed in patients with cirrhosis and liver failure to reduce mortality by 50% and decrease the development of liver-related complications. The indication for pentoxifylline in these patients is based on different reasons. Proinflammatory cytokine production is increased in these patients and has deleterious effects on the liver and other organs. 1,2 Pentoxifylline administration has been found to affect numerous steps in the cytokine inflammatory pathway, either directly or indirectly by inhibition of TNF-alpha. [22] [23] [24] [25] In addition, clinical trials in small numbers of patients have shown beneficial effects of pentoxifylline on liver tests 16, 17, 26 and pentoxifylline improved survival in one trial in patients with severe acute alcoholic hepatitis. 18 In the present study, the proportions of patients surviving at 2 and 6 months were not different between patients treated with pentoxifylline and those receiving a placebo.
Since the number of patients with early hepatocellular carcinoma was higher in the pentoxifylline group than in the placebo group, an analysis was performed without these patients and the results showed again no significant difference in the mortality between the 2 groups indicating that the presence of hepatocellular carcinoma was not the cause of the lack of effect of pentoxifylline. Obviously the a priori hypothesis of a 50% reduction of mortality at 2 months was too optimistic. However, the sample size, the low frequency of events in the first 2 months, and the significant reduction of complications or death at 2 months make it difficult to draw any definite negative conclusions for the efficacy of pentoxifylline. If pentoxifylline reduces complications by 15% at 12 months, a mortality of 50% is impossible to achieve. Therefore a larger study would need to be performed with more than 1,000 patients to detect a 15%
difference in mortality at 6 months.
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The analysis of mortality in patients with alcoholic hepatitis shows no significant difference between patients treated with pentoxifylline and those receiving a placebo. These results are similar to a preliminary report showing that pentoxifylline decreased the risk of renal impairment and improved disease severity but failed to improve survival 26 but differ from an American trial where pentoxifylline significantly decreased mortality. 18 However, the American trial cannot be directly compared to the current trial because patients in our study with a Maddrey discriminant function score above 32 received corticosteroids with or without addition of pentoxifylline whereas in the American study they received either placebo or pentoxifylline without additional corticosteroids. Also, the current study randomized patients with alcoholic hepatitis and a discriminant function score of 32 or less to either pentoxifylline or placebo while the American trial did not enroll patients with mild alcoholic hepatitis. The discordant results between the current trial and the American trial among patients with severe alcoholic hepatitis suggest that the severity of the disease and the management of these patients may have differed between the 2 trials and that further clinical studies are needed.
The effect of pentoxifylline on mortality was also evaluated in a subgroup of patients who
were not receiving either antibiotics or beta-blockers or corticosteroids since these three types of drugs significantly reduce cytokine production by different mechanisms. [27] [28] [29] The results showed a lower mortality in pentoxifylline patients compared to those receiving a placebo although the difference was not significant. The significant difference in mortality at 6 months calculated by per protocol analysis suggests, however, that pentoxifylline might be useful in selected patients.
Except for the lack of power, there is no clear explanation for the lack of beneficial effects of pentoxifylline treatment on mortality in patients with cirrhosis and liver failure. However, certain comments can be made. Most patients in our study died within 2 months after admission from multiple organ failure or liver-related complications. This is expected by published estimation of mortality in this category of patients. 30 Thus it is possible that the pentoxifylline treatment period was too short to have an effect on these severly ill patients or these patients
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were too sick to benefit from treatment with pentoxifylline. This hypothesis is, at least in part,
confirmed by the multivariate analysis where elevated MELD score, a well known classification of the severity of cirrhosis and predictor of survival 31 is associated with mortality in these patients.
A significant correlation between serum TNF-alpha concentration at admission and mortality was observed only when the entire cohort was analyzed. This result is similar to one previous study performed in patients with severe alcoholic hepatitis 31 but is different from another trial performed in alcoholic patients. 18 The lack of a correlation has also been reported in patients with alcoholic hepatitis where soluble TNF receptor-1 (sTNF-R) but not serum TNFalpha levels predicts the short-term mortality. 33 The absence of decrease in serum TNF-alpha levels in patients receiving pentoxifylline remains unclear. One explanation is either that the dose of pentoxifylline was insufficient to affect TNF-alpha synthesis or that pentoxifylline acts via a different mechanim such as cyclic nucleotide regulation. In addition, it has been shown that TNF-alpha inhibitors such as infliximab and etanercept are not effective for the treatment of patients with alcoholic hepatitis. 34, 35 This trial demonstrates that pentoxifylline treatment significantly reduced the risk of liverrelated complications compared to placebo in patients with advanced cirrhosis. These complications included bacterial infection, renal insufficiency and hepatic encephalopathy but not gastrointestinal hemorrhage. 19 Since pentoxifylline prevents intestinal bacterial translocation and subsequent spontaneous bacterial peritonitis 19, 36 this may explain the beneficial role of pentoxifylline in the prevention of bacterial infection in patients with advanced cirrhosis. The reduction of renal insufficiency by pentoxifylline has previously been demonstrated in patients with severe alcoholic hepatitis. 18, 26 In previous trials, the development of renal impairment occurred less frequently in pentoxifylline treated patients than in control patients. 18 The exact mechanisms of pentoxifylline on renal function remain to be determined but the results of these trials suggest an association between TNF-alpha overproduction and renal dysfunction. The risk
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A C C E P T E D M A N U S C R I P T 14 of hepatic encephalopathy was also significantly decreased in patients in the pentoxifylline group compared to the placebo group. The relationship between cytokines and encephalopathy has not been fully investigated but a correlation exists between serum TNF-alpha concentrations and the severity of hepatic encephalopathy, suggesting a potential role of TNF-alpha production and the development of this complication. 37 In contrast to other liver-related complications, the occurrence of gastrointestinal hemorrhage was not modified by pentoxifylline treatment. The small number of patients with gastrointestinal bleeding in this study may explain this negative result. Multivariate analysis confirmed these results and showed that only pentoxifylline treatment was associated with a lower occurrence of liver related complications. However, the beneficial effects of pentoxifylline on survival without complications were even more important.
These results suggest that pentoxifylline might be administered to patients with advanced cirrhosis but since it was not the primary endpoint, further trials are needed.
Pentoxifylline was well tolerated in patients with advanced cirrhosis. Pentoxifylline was only interrupted in the first month of administration in 7 patients for gastrointestinal disorders which are well known adverse events for this drug. In 4 patients, the drug was continued after a reduction in pentoxifylline dose suggesting that side effects may be dose dependent.
In conclusion, no decrease in mortality was observed in this study with pentoxifylline treatment in patients with cirrhosis and liver failure. However, pentoxifylline treatment limited the risk of liver-related complications, in particular the development of bacterial infection, renal failure and hepatic encephalopathy and reduced the mortality in patients without complications.
The relatively short period of treatment may explain the lack of beneficial effect of pentoxifylline on mortality even though pentoxifylline reduces the development of complications.
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Legend to the Figures   Figure 1. Flow chart of the patients included in the study. A C C E P T E D M A N U S C R I P T 
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